The following clinical trials are currently recruiting participants. If you would like more information regarding the trial or how to participate, please contact the study coordinator.
|Trial Name||Sponsor||Summary||Details||Study Coordinator|
|FIND-CKD||Bayer||Phase 3 Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD).||Participants will take finerenone or a placebo once a day as tablets by mouth for a period of 32 months.|
|Neptune||National Institutes of Health, NIDDK, Nephcure Kidney International, University of Michigan||The purpose of this multi-center, observational research study is to learn more about four diseases which cause nephrotic syndrome: Focal Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD), and Membranous Nephropathy (MN) and Alport syndrome. By collecting health information and laboratory samples from individuals who have these diseases and by making this information available to researchers, we hope to gain new knowledge about these diseases and to find better treatments for them.||
|Cognitive Impairment||KUMC Kidney Institute||Evaluation of the changes in memory and thinking before and after transplant in relation to changes seen in images of the brain||
|EPOC PKD||NIH||This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), The long-term goal is to develop new knowledge of biomarkers that indicate changes in the disease progression. An understanding of biomarkers will benefit PKD patients as new therapies are being developed and tested.||
|FALCON||REATA||FALCON is a Phase 3 clinical study evaluating the effectiveness and safety of bardoxolone methyl (an oral investigational drug) in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).||
|Fabry Registry||Genzyme||Collection of clinical data on patients with Fabry disease around the world in an effort to help health professionals involved in treatment or diagnosis better understand Fabry Disease and its management||
|Renal Tubular Function in Living Donors||Investigator initiated||Evaluate the renal tubular function pre- and post-nephrectomy in living donors.||
|Cognitive Function-Everolimus||Novartis, llT||Title: Alterations in Cognitive Function and Cerebral Blood Flow after Conversion from Calcineurin Inhibitors to Everolimus. This single center longitudinal 12 weeks observational study will determine whether conversion from calcineurin inhibitor (Tacrolimus) to an mTOR inhibitor, Everolimus, is associated with improvement in cognition and cerebral blood flow.||
|PKD Registry||KUMC Jared Grantham Kidney Institute||The University of Kansas Medical Center is establishing a biorepository of blood and urine samples from adults with Polycystic Kidney Disease (PKD) in order to provide specimens to investigators for the discovery of biomarkers.
Biomarkers may help monitor PKD progression and determine the effectiveness of new treatments
Study Coordinator Contact Information
Cathy Creed, RN
Debbie Griffin, RN, CDE